<?xml version="1.0" encoding="UTF-8"?>
<p id="p0060">OWSVI has an official budget of $10 billion, and can access additional funds through BARDA (
 <xref rid="bib9" ref-type="bibr">9</xref>). Over $2 billion has already been allocated, and 5 vaccines, most in the preclinical phase, have been identified as promising enough to warrant OWSVI funding. AstraZeneca, in partnership with Oxford University, has been awarded over $1 billion in BARDA funding for the development, production, and delivery by next autumn of a vaccine that is currently recruiting for phase II/III trials while they complete phase I (
 <xref rid="bib11" ref-type="bibr">11</xref>). Although there are many questions about OWSVI, including concerns over potentially significant commercial and political conflicts of interest within the program leadership, and questions of whether the program will stifle critical coordination and cooperation among other global entities trying to produce a vaccine, it is nevertheless enlightening to examine the strategies OWSVI is deploying to realize such a remarkable timeline (
 <xref rid="fig1" ref-type="fig">FigureÂ 1</xref>).
</p>
